Filana Therapeutics Inc. research and ratings by Barron's. View FLNA revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

As FiercePharma explains, the company is attempting to rebrand itself in the wake of a Justice Department investigation, a class-action lawsuit, and a failed attempt at treating Alzheimer’s. Plus: The ...

Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company focused on developing novel medicines to modulate the filamin ...

New corporate identity reflects the Company’s mission to develop novel medicines to modulate filamin A and address unmet needs in treating ...

Two Manchester researchers, Professor Bruce Grieve and Professor Hujun Yin, were recognised with the Pioneering UK-US Breakthroughs (PUB) award, by the UK Research and Innovation in the British ...

Cassava Sciences rebrands to Filana Therapeutics (FLNA) on March 11, 2026, focusing on filamin A CNS therapies for TSC epilepsy—get the latest update.

Weis Markets Inc (WMK) is expected to report for 4Q. Yext Inc (YEXT) is expected to report $0.06 for 4Q. Zenas BioPharma Inc (ZBIO) is expected to report for 4Q. enCore Energy Corp (EU.V) is expected ...